Literature DB >> 26424429

Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia.

Ahmed El-Missiry1, Amira Elbatrawy2, Marwa El Missiry2, Dalia Abdel Moneim2, Ramy Ali2, Heba Essawy2.   

Abstract

BACKGROUND: Medication non-adherence presents a considerable problem in patients with schizophrenia. Cognitive and executive functions can affect adherence. The association between medication non-adherence and cognitive impairment in schizophrenia is under investigated with limited and conflicting research data. PURPOSE OF THE STUDY: To prospectively assess the rate of drug adherence among a sample of patients with schizophrenia and to compare the cognitive and executive functions between adherent and non-adherent patients. SUBJECTS AND METHODS: 109 patients with schizophrenia diagnosed according to the DSM-IV classification were initially assessed by the Wechsler Adult Intelligence Scale (WAIS), Wechsler Memory Scale-Revised (WMS-R) and Wisconsin Card Sorting Test (WCST) and six months later by the Brief Adherence Rating Scale (BARS).
RESULTS: 68.8% were non-adherent to their antipsychotic medication. Adherent patients (31.2%) had significantly higher mean scores for the total, verbal and performance IQ. They had significantly higher mean scores in most of WMS subtests (orientation, information, verbal paired association, digit span, visual memory span), and higher mean scores for; total correct, conceptual level response, percentage and categories completed on the WSCT subscales (P < 0.0001). Whereas the non-adherent group had higher mean scores in; trials administered, total errors, perseverative responses, and perseverative errors (P < 0.0001). In a step regression analysis, digit span, conceptualization, total and percentage of errors were putative predictors of non-adherence.
CONCLUSION: Cognitive deficits, especially verbal memory and executive functions were the strongest patients' related factors associated with non adherence to medication. Psychiatrists ought to consider possible cognitive factors influencing adherence to enable offering proper interventions.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adherence; Cognitive functions; Memory; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26424429     DOI: 10.1016/j.jpsychires.2015.09.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Long-Term Antipsychotic Effectiveness and Comparison of the Efficacy of Monotherapy and Polypharmacy in Schizophrenia: A 3-Years Follow-Up "Real World" Study in China.

Authors:  Lei Zhang; Sidi He; Luyao He; Wenjuan Yu; Shen He; Yange Li; Yimin Yu; Qingshan Zheng; Jingjing Huang; Yifeng Shen; Huafang Li
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

2.  The Risk of Sexually Transmitted Infections Following First-Episode Schizophrenia Among Adolescents and Young Adults: A Cohort Study of 220 545 Subjects.

Authors:  Chih-Sung Liang; Ya-Mei Bai; Ju-Wei Hsu; Kai-Lin Huang; Nai-Ying Ko; Hsuan-Te Chu; Ta-Chuan Yeh; Shih-Jen Tsai; Tzeng-Ji Chen; Mu-Hong Chen
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

3.  Dysfunction of Cognition Patterns Measured by MATRICS Consensus Cognitive Battery (MCCB) among First Episode Schizophrenia Patients and Their Biological Parents.

Authors:  Aiai Cao; Ting Shen; Haibin Li; Chuangxin Wu; Marita McCabe; David Mellor; Linda Byrne; Jie Zhang; Jia Huang; Daihui Peng; Yifeng Xu
Journal:  Shanghai Arch Psychiatry       Date:  2017-06-25

4.  Factors Influencing Rehospitalisation of Patients with Schizophrenia in Japan: A 1-year Longitudinal Study.

Authors:  Takeshi Shimada; Ai Nishi; Tomotaka Yoshida; Sachie Tanaka; Masayoshi Kobayashi
Journal:  Hong Kong J Occup Ther       Date:  2016-12-29       Impact factor: 0.917

Review 5.  Assessing cognition in people with severe mental disorders in low- and middle-income countries: a systematic review of assessment measures.

Authors:  Yohannes Gebreegziabhere Haile; Kassahun Habatmu; Andualem Derese; Hetta Gouse; Stephen M Lawrie; Matteo Cella; Atalay Alem
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-06-18       Impact factor: 4.328

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.